FBT vs. KNOS, SGE, DARK, SXS, SCT, RSW, CCC, NETW, OXIG, and BYIT
Should you be buying First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation stock or one of its competitors? The main competitors of First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation include Kainos Group (KNOS), The Sage Group (SGE), Darktrace (DARK), Spectris (SXS), Softcat (SCT), Renishaw (RSW), Computacenter (CCC), Network International (NETW), Oxford Instruments (OXIG), and Bytes Technology Group (BYIT). These companies are all part of the "computer and technology" sector.
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT) and Kainos Group (LON:KNOS) are both computer and technology companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, community ranking, valuation, risk, earnings, profitability, media sentiment and institutional ownership.
43.3% of Kainos Group shares are owned by institutional investors. 37.6% of Kainos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Kainos Group has higher revenue and earnings than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is trading at a lower price-to-earnings ratio than Kainos Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kainos Group had 3 more articles in the media than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. MarketBeat recorded 4 mentions for Kainos Group and 1 mentions for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation. First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's average media sentiment score of 1.53 beat Kainos Group's score of 0.66 indicating that First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation is being referred to more favorably in the media.
Kainos Group received 169 more outperform votes than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation when rated by MarketBeat users. Likewise, 72.16% of users gave Kainos Group an outperform vote while only 66.67% of users gave First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation an outperform vote.
Kainos Group has a net margin of 10.79% compared to First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's net margin of 0.00%. Kainos Group's return on equity of 32.92% beat First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation's return on equity.
Kainos Group has a consensus target price of GBX 1,280, indicating a potential upside of 25.24%. Given Kainos Group's higher possible upside, analysts clearly believe Kainos Group is more favorable than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation.
Summary
Kainos Group beats First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation on 13 of the 15 factors compared between the two stocks.
Get First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Competitors List
Related Companies and Tools
